Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9H875
UPID:
PKRI1_HUMAN
Alternative names:
-
Alternative UPACC:
Q9H875; B4DGM2; Q8NDM6; Q96CF8
Background:
PRKR-interacting protein 1 plays a crucial role in pre-mRNA splicing as part of the spliceosome complex, essential for gene expression regulation. It also binds double-stranded RNA and can inhibit EIF2AK2 kinase activity, suggesting a multifunctional role in cellular processes.
Therapeutic significance:
Understanding the role of PRKR-interacting protein 1 could open doors to potential therapeutic strategies, offering new avenues for drug discovery and development.